Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure

Hilal Hachem, Amandeep Godara, Courtney Schroeder, Daniel Fein, Hashim Mann, Christian Lawlor, Jill Marshall, Andreas Klein, Debra Poutsiaka, Janis L. Breeze, Raghav Joshi, Paul Mathew
doi: https://doi.org/10.1101/2021.05.29.21258010

Data Availability

Clinical and cytokine data are represented in the report and may be supplemented e.g. raw cytokine data, on request.

Back to top
Posted June 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure
Hilal Hachem, Amandeep Godara, Courtney Schroeder, Daniel Fein, Hashim Mann, Christian Lawlor, Jill Marshall, Andreas Klein, Debra Poutsiaka, Janis L. Breeze, Raghav Joshi, Paul Mathew
medRxiv 2021.05.29.21258010; doi: https://doi.org/10.1101/2021.05.29.21258010
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area